In Certain Types of Lung Cancer, Targeted Drug Tagrisso Slashed Recurrence Rates, New Study Says

Published Sep 22, 2020

In Certain Types of Lung Cancer, Targeted Drug Tagrisso Slashed Recurrence Rates, New Study Says

Already approved for EGFR-positive metastatic non-small cell lung cancer, osimertinib (Tagrisso ) brings major benefits in early cancer, too.

NOW
PLAYING
Radio Host Rush Limbaugh Battles Late-Stage Lung Cancer-- What Are the Options For Treatment? So Often It's About Making It To Milestones
NOW
PLAYING
Keytruda Extends Life for Those Fighting Hodgkin Lymphoma & It's Now FDA-Approved as Treatment
NOW
PLAYING
$21 Billion Bet On Cancer Drug Trodelvy: What Does It Mean for Patients?
NOW
PLAYING
5 Truths Sharon Osbourne Learned From Colon Cancer: 'You Realize How Lucky You Are to Be Alive'
NOW
PLAYING
10 Public Figures Whose Lung Cancer Diagnosis Helped Raise Awareness for the Disease
NOW
PLAYING
New Lung Cancer Drug, Retevmo, So Effective It Gave Musician His Life Back
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.